SE8903777L - Liposome/doxorubicin, komposition och foerfarande - Google Patents

Liposome/doxorubicin, komposition och foerfarande

Info

Publication number
SE8903777L
SE8903777L SE8903777A SE8903777A SE8903777L SE 8903777 L SE8903777 L SE 8903777L SE 8903777 A SE8903777 A SE 8903777A SE 8903777 A SE8903777 A SE 8903777A SE 8903777 L SE8903777 L SE 8903777L
Authority
SE
Sweden
Prior art keywords
liposome
composition
doxorubicin
procedure
concentrate
Prior art date
Application number
SE8903777A
Other languages
English (en)
Other versions
SE8903777D0 (sv
Inventor
Huang A Hei-Leung
Original Assignee
Liposome Technology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liposome Technology Inc filed Critical Liposome Technology Inc
Publication of SE8903777D0 publication Critical patent/SE8903777D0/sv
Publication of SE8903777L publication Critical patent/SE8903777L/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/829—Liposomes, e.g. encapsulation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
SE8903777A 1987-05-18 1989-11-10 Liposome/doxorubicin, komposition och foerfarande SE8903777L (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/051,418 US4927571A (en) 1987-05-18 1987-05-18 Preparation of injectable doxorubicin/liposome suspension
PCT/US1988/001573 WO1988009168A1 (en) 1987-05-18 1988-05-12 Liposome/doxorubicin composition and method

Publications (2)

Publication Number Publication Date
SE8903777D0 SE8903777D0 (sv) 1989-11-10
SE8903777L true SE8903777L (sv) 1989-11-10

Family

ID=21971185

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8903777A SE8903777L (sv) 1987-05-18 1989-11-10 Liposome/doxorubicin, komposition och foerfarande

Country Status (12)

Country Link
US (1) US4927571A (sv)
EP (1) EP0362258A4 (sv)
JP (1) JPH02503558A (sv)
AU (1) AU1790688A (sv)
FI (1) FI895510A7 (sv)
HU (1) HUT51900A (sv)
IL (1) IL86412A0 (sv)
NZ (1) NZ224644A (sv)
PT (1) PT87498B (sv)
SE (1) SE8903777L (sv)
WO (1) WO1988009168A1 (sv)
ZA (1) ZA883487B (sv)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077056A (en) * 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5736155A (en) * 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
MX9203808A (es) * 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
AU635587B2 (en) * 1989-10-27 1993-03-25 Nexstar Pharmaceuticals, Inc. Reconstitution method
US5053406A (en) * 1989-12-13 1991-10-01 Glycomed, Inc. Compositions and methods for preventing and treating rotaviral infections
US5152999A (en) * 1990-04-24 1992-10-06 Fujisawa Pharmaceutical Co., Ltd. Liposome preparation
US5104546A (en) * 1990-07-03 1992-04-14 Aluminum Company Of America Pyrogens separations by ceramic ultrafiltration
US6060080A (en) * 1990-07-16 2000-05-09 Daiichi Pharmaceutical Co., Ltd. Liposomal products
JP3533215B2 (ja) * 1990-07-31 2004-05-31 ザ リポソーム カンパニー，インコーポレイテッド アミノ酸及びペプチドのリポソーム内への蓄積
CA2088975A1 (en) * 1990-08-08 1992-02-09 Anthony H. Huang Stable doxorubicin/liposome composition
US5242595A (en) * 1991-04-25 1993-09-07 U.S. Filter/Illinois Water Treatment, Inc. Bacteria removal by ceramic microfiltration
ES2072223B1 (es) * 1993-11-25 1996-03-16 Lipotec Sa Liposomas encapsulando doxorubicina.
CA2202103C (en) * 1996-04-11 2007-01-09 Toshiaki Tagawa Method for preparing closed vesicles
DE19639811A1 (de) * 1996-09-27 1998-04-02 Artur Herzog Dr Mesmer Verwendung einer Liposomenlösung zur Verstärkung der Wirksamkeit und/oder Verminderung der Toxizität von Arzneimitteln
IL131008A (en) * 1997-02-05 2003-06-24 Upjohn Co Lipid complexes and liposomes of highly insoluble platinum complex dicarboxylate
US7314637B1 (en) 1999-06-29 2008-01-01 Neopharm, Inc. Method of administering liposomal encapsulated taxane
US6146659A (en) * 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
US20050118250A1 (en) * 2001-11-13 2005-06-02 Paul Tardi Lipid carrier compositions with enhanced blood stability
US20050118249A1 (en) * 2001-11-13 2005-06-02 Murray Webb Lipid carrier compositions and methods for improved drug retention
US20040219201A1 (en) * 2001-12-06 2004-11-04 Yechezkel Barenholz Tempamine compositions and methods of use
US20040082521A1 (en) * 2002-03-29 2004-04-29 Azaya Therapeutics Inc. Novel formulations of digitalis glycosides for treating cell-proliferative and other diseases
DE10222561B4 (de) * 2002-05-17 2009-12-10 Dr. Franz Köhler Chemie GmbH Protektive Lösung zur Verhinderung von Ischämieschäden
HUE031505T2 (en) * 2002-06-26 2017-07-28 Syncore Biotechnology Co Ltd A method of producing a cationic liposomal composition comprising a lipophilic compound
US20040034336A1 (en) * 2002-08-08 2004-02-19 Neal Scott Charged liposomes/micelles with encapsulted medical compounds
WO2004057959A2 (en) * 2002-12-20 2004-07-15 Generipharm, Inc. Intracutaneous injection
CN1700906A (zh) * 2003-02-03 2005-11-23 新药物公司 稳定的无菌过滤性脂质体包封的紫杉烷和其他抗肿瘤药物
US7517342B2 (en) * 2003-04-29 2009-04-14 Boston Scientific Scimed, Inc. Polymer coated device for electrically medicated drug delivery
EP1809254A2 (en) * 2004-10-28 2007-07-25 Alza Corporation Lyophilized liposome formulations and method
CN100376249C (zh) * 2004-12-21 2008-03-26 台湾东洋药品工业股份有限公司 多柔比星脂质体及其制备方法和用途
US8148338B2 (en) * 2006-02-22 2012-04-03 Supratek Pharma Inc. Doxorubicin formulations for anti-cancer use
FR2900576B1 (fr) 2006-05-03 2008-09-19 Centre Nat Rech Scient Procede de concentration extemporanee et reversible de liposomes.
US20100068251A1 (en) * 2006-10-10 2010-03-18 Jina Pharmaceuticals, Inc. Aqueous Systems For The Preparation Of Lipid Based Pharmaceutical Compounds; Compositions, Methods, And Uses Thereof
US20100260830A1 (en) * 2009-04-08 2010-10-14 Brian A Salvatore Liposomal Formulations of Tocopheryl Amides
EP2253308A1 (en) 2009-05-22 2010-11-24 Ludwig-Maximilians-Universität München Pharmaceutical composition comprising microbubbles for targeted tumor therapy
WO2012012460A1 (en) 2010-07-19 2012-01-26 Xeris Pharmaceuticals, Inc. Stable glucagon formulations for the treatment of hypoglycemia
CN105853348B (zh) 2011-03-10 2019-08-30 Xeris药物公司 肠胃外注射用稳定溶液
JP5929907B2 (ja) * 2011-05-17 2016-06-08 三菱瓦斯化学株式会社 ピロロキノリンキノンと糖を含むリポソーム
KR102284689B1 (ko) 2011-10-21 2021-08-02 셀라토 파마슈티칼즈, 인코포레이티드 동결건조된 리포좀
ES2574761T3 (es) 2011-10-31 2016-06-21 Xeris Pharmaceuticals, Inc. Formulaciones para el tratamiento de la diabetes
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
AU2015300944B2 (en) 2014-08-06 2019-07-11 Xeris Pharmaceuticals, Inc. Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
KR102716928B1 (ko) 2015-07-22 2024-10-11 닛토덴코 가부시키가이샤 나노 입자 동결건조물 형태를 위한 조성물 및 방법
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
BR112019024987A2 (pt) 2017-06-02 2020-06-16 Xeris Pharmaceuticals, Inc. Formulações de fármaco de molécula pequena resistente à precipitação
EP3989978B1 (en) 2019-06-28 2025-12-17 Board of Regents, The University of Texas System Preparation of preliposomal annamycin lyophilizate
WO2020264161A1 (en) 2019-06-28 2020-12-30 Donald Picker Method of reconstituting liposomal annamycin
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
EP4312536A1 (en) 2021-04-01 2024-02-07 Vestaron Corporation Liposome formulations for pesticide delivery and methods for producing and using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4460577A (en) * 1977-09-30 1984-07-17 Farmitalia Carlo Erba S.P.A. Pharmaceutical compositions consisting or consisting essentially of liposomes, and processes for making same
US4515736A (en) * 1983-05-12 1985-05-07 The Regents Of The University Of California Method for encapsulating materials into liposomes
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS60208910A (ja) * 1984-03-31 1985-10-21 Green Cross Corp:The 水難溶性薬物・リン脂質複合体の製造方法
CA1270198A (en) * 1984-08-08 1990-06-12 Marcel B. Bally Encapsulation of antineoplastic agents in liposomes
US4766046A (en) * 1985-09-27 1988-08-23 Liposome Technology, Inc. Stabilized liposome/amphotericin composition and method
US4797285A (en) * 1985-12-06 1989-01-10 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Lipsome/anthraquinone drug composition and method

Also Published As

Publication number Publication date
WO1988009168A1 (en) 1988-12-01
SE8903777D0 (sv) 1989-11-10
AU1790688A (en) 1988-12-21
EP0362258A4 (en) 1990-12-27
JPH02503558A (ja) 1990-10-25
IL86412A0 (en) 1988-11-15
NZ224644A (en) 1990-12-21
PT87498B (pt) 1992-09-30
PT87498A (pt) 1989-05-31
HUT51900A (en) 1990-06-28
US4927571A (en) 1990-05-22
EP0362258A1 (en) 1990-04-11
FI895510A0 (fi) 1989-11-17
FI895510A7 (sv) 1989-11-17
ZA883487B (en) 1988-11-21

Similar Documents

Publication Publication Date Title
SE8903777D0 (sv) Liposome/doxorubicin, komposition och foerfarande
DK322188D0 (da) Fremgangsmaade til fremstilling af protein
AU586897B2 (en) Thrombin preparations
CA2103887A1 (en) Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
SE9002522L (sv) Metod foer framstaellning av en farmaceutisk komposition i form av mikropartiklar
GB9626483D0 (en) Helicobacter proteins and vaccines
DE3582272D1 (de) Antigenische zubereitungen und isolierung von solchen zubereitungen.
AU539195B2 (en) Determination of low density lipoproteins
GR3003631T3 (sv)
ES2044849T3 (es) Un procedimiento para preparar un glicosido de flavona.
HU9202435D0 (en) Blood factors produced by a recombinant process, method for expressing said bloode factors and recombinant vaccina viruses utilized in said method
DK0666754T3 (da) Syntetisk lungesurfactant med antioxidant-egenskaber
KR860003825A (ko) 안정한 현탁액 제조용 고체 약물제형의 제조방법
SE8704157L (sv) Superparamagnetiska partiklar och foerfarande foer framstaellning daerav samt anvaendning
SE8400118L (sv) Substituerade karboxi-tiazolo/3,2-a/pyrimidinderivat och forfarande for deras framstellning
SE8404130L (sv) Nya injecerbara kompositioner
ITMI932171A1 (it) Procedimento per l'estrazione di colori naturali mediante bentonite
GR3036125T3 (en) Recombinant proteins having the immunoreactivity of Hepatitis B virus e antigens (HBeAg), method for their production and their application in immunoassays and as vaccines.
SE8903154L (sv) Foerfaringssaett och apparat foer foersegling av pappersark
IT8221931A0 (it) Metodo per la preparazione di 16 alfa-cloro derivati di pregneni e pregnadieni non sostituiti in posizione 17.
SG13094G (en) Stabilization of the preservative thiomersal in ophthalmic pharmaceutical compositions.

Legal Events

Date Code Title Description
NAV Patent application has lapsed

Ref document number: 8903777-4

Effective date: 19910517

Format of ref document f/p: F